H.C. Wainwright Keeps Their Buy Rating on Precision BioSciences (DTIL)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTILResearch Report) today and set a price target of $17.00. The company’s shares closed yesterday at $1.23.

Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, Gossamer Bio, and Milestone Pharmaceuticals. According to TipRanks, Trucchio has an average return of -16.2% and a 30.51% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $7.75 average price target.

See the top stocks recommended by analysts >>

Based on Precision BioSciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.36 million and a GAAP net loss of $23.95 million. In comparison, last year the company earned a revenue of $24.04 million and had a GAAP net loss of $11.28 million

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTIL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Read More on DTIL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More